Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Mass spectroscopy-defined neoepitopes are a rich source of tumor rejection-mediating neoepitopes in a mouse sarcoma

Hakimeh Ebrahimi-Nik, Tatiana Shcheglova, Justine Michaux, HuiSong Pak, Elham Sherafat, Sahar Al Seesi, Ion I Mandoiu, Michal Bassani-Sternberg and Pramod K Srivastava
J Immunol May 1, 2019, 202 (1 Supplement) 70.13;
Hakimeh Ebrahimi-Nik
1University of Connecticut, School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatiana Shcheglova
1University of Connecticut, School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Justine Michaux
2Ludwig Centre for Cancer Research, University of Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HuiSong Pak
2Ludwig Centre for Cancer Research, University of Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elham Sherafat
3Department of Computer Sciences, University of Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sahar Al Seesi
3Department of Computer Sciences, University of Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ion I Mandoiu
3Department of Computer Sciences, University of Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michal Bassani-Sternberg
2Ludwig Centre for Cancer Research, University of Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pramod K Srivastava
1University of Connecticut, School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Using tandem mass spectroscopy (MS), we identified 3646 unique sequences among peptides eluted from purified Kd and Dd MHC I molecules of the BALB/c fibrosarcoma Meth A. These peptides were cross-referenced with the output of neoepitopes predicted for this tumor by our prediction pipeline CCCP (Cross Consensus Calling Platform). Eleven (11) of the eluted peptides were identified as neoepitopes and eight neoepitopes (of 11) were confirmed by targeted MS.

Each neoepitope was used to immunize BALB/c mice (twice, one week apart, using precise neoepitopes along with bone marrow-derived dendritic cells); mice were challenged with Meth A cells one week after the last immunization, and tumor growth was monitored in individual mice. In parallel, immunized mice were tested for CD8+ T cells to the neoepitopes using tetramer staining and interferon g secretion by CD8 cells.

Four of the eight neoepitopes elicited rejection of Meth A fibrosarcoma; two of the four neoepitopes elicited highly potent tumor rejection, while the other two elicited statistically significant but weaker tumor rejection. Of the two strong neoepitopes, only one elicited a measurable CD8 response. Both weak neoepitopes elicited measurable CD8 responses. Of the four neoepitopes that did not elicit tumor rejection, only one elicited a measurable CD8 response; this CD8 response was the strongest of all CD8 responses detected.

These observations indicate that MS-defined neoepitopes can be a rich source of neoepitopes that can mediate tumor rejection. Further, they highlight the fact that CD8 responses are not a good predictive surrogates for tumor rejection.

  • Copyright © 2019 by The American Association of Immunologists, Inc.
Previous
Back to top

In this issue

The Journal of Immunology
Vol. 202, Issue 1 Supplement
1 May 2019
  • Table of Contents
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Mass spectroscopy-defined neoepitopes are a rich source of tumor rejection-mediating neoepitopes in a mouse sarcoma
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Mass spectroscopy-defined neoepitopes are a rich source of tumor rejection-mediating neoepitopes in a mouse sarcoma
Hakimeh Ebrahimi-Nik, Tatiana Shcheglova, Justine Michaux, HuiSong Pak, Elham Sherafat, Sahar Al Seesi, Ion I Mandoiu, Michal Bassani-Sternberg, Pramod K Srivastava
The Journal of Immunology May 1, 2019, 202 (1 Supplement) 70.13;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Mass spectroscopy-defined neoepitopes are a rich source of tumor rejection-mediating neoepitopes in a mouse sarcoma
Hakimeh Ebrahimi-Nik, Tatiana Shcheglova, Justine Michaux, HuiSong Pak, Elham Sherafat, Sahar Al Seesi, Ion I Mandoiu, Michal Bassani-Sternberg, Pramod K Srivastava
The Journal of Immunology May 1, 2019, 202 (1 Supplement) 70.13;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Info & Metrics

Related Articles

Cited By...

More in this TOC Section

  • Natural Adjuvants for in situ Vaccination Lymphoma Immunotherapy
  • Kinase domain deleted engineered HER2 could elicit efficient tumor immune response
  • Assessing the impact of neoantigen load on checkpoint blockade efficacy
Show more Adjuvant, Antigen Presentation, and Peptide-Based Vaccines for Immunotherapy

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • Public Access
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2021 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606